These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11043451)

  • 21. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of elastic liquid-state vesicle on apomorphine iontophoresis transport through human skin in vitro.
    Li GL; Danhof M; Bouwstra JA
    Pharm Res; 2001 Nov; 18(11):1627-30. PubMed ID: 11758773
    [No Abstract]   [Full Text] [Related]  

  • 23. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 24. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
    Bibbiani F; Costantini LC; Patel R; Chase TN
    Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of tolcapone on plasma and striatal apomorphine disposition in rats.
    Coudoré F; Durif F; Duroux E; Eschalier A; Fialip J
    Neuroreport; 1997 Mar; 8(4):877-80. PubMed ID: 9141056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.
    Regnier-Delplace C; Thillaye du Boullay O; Siepmann F; Martin-Vaca B; Degrave N; Demonchaux P; Jentzer O; Bourissou D; Siepmann J
    Int J Pharm; 2013 Feb; 443(1-2):68-79. PubMed ID: 23313920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo and in vitro release of macromolecules from polymeric drug delivery systems.
    Brown LR; Wei CL; Langer R
    J Pharm Sci; 1983 Oct; 72(10):1181-5. PubMed ID: 6644569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
    van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
    Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
    Grosset KA; Malek N; Morgan F; Grosset DG
    Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
    Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
    van der Geest R; van Laar T; Kruger PP; Gubbens-Stibbe JM; Boddé HE; Roos RA; Danhof M
    Clin Neuropharmacol; 1998; 21(3):159-68. PubMed ID: 9617507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applications of ethylene vinyl acetate copolymers (EVA) in drug delivery systems.
    Schneider C; Langer R; Loveday D; Hair D
    J Control Release; 2017 Sep; 262():284-295. PubMed ID: 28789964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease.
    Todorova A; Ray Chaudhuri K
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1073-8. PubMed ID: 24051336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.
    Bhidayasiri R; Sringean J; Anan C; Boonpang K; Thanawattano C; Ray Chaudhuri K
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S36-S41. PubMed ID: 27939326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of route and frequency of administration of apomorphine on growth hormone release in African catfish (Clarias gariepinus).
    Lescroart O; Roelants I; Cauwenberghs N; De Schrijver R; Kühn ER; Ollevier F
    Life Sci; 1997; 60(20):1771-9. PubMed ID: 9150417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D(2) activity of R-(-)-apomorphine and selected analogs: a microdialysis study.
    Rodenhuis N; Dijkstra D; de Boer P; Vermeulen ES; Timmerman W; Wikström HV
    Eur J Pharmacol; 2000 Jan; 387(1):39-45. PubMed ID: 10633158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats.
    Sabel BA; Dominiak P; Häuser W; During MJ; Freese A
    J Pharmacol Exp Ther; 1990 Nov; 255(2):914-22. PubMed ID: 2243358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.